| Lauren Michelle Friedkin, OTR/L | |
|
925 Bear Corbitt Rd, Bear, DE 19701-1323 | |
| (302) 454-2400 | |
| Not Available |
| Full Name | Lauren Michelle Friedkin |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 925 Bear Corbitt Rd, Bear, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578101812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | U1-0002096 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Michelle Friedkin, OTR/L 1176 Creekside Dr, Wilmington, DE 19804-3941 Ph: (215) 500-8232 | Lauren Michelle Friedkin, OTR/L 925 Bear Corbitt Rd, Bear, DE 19701-1323 Ph: (302) 454-2400 |
News Archive
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').
The National Institutes of Health announced approval of embryonic stem cell lines for federally funded research. The Washington Post reports the decision is "opening the way for millions of taxpayer dollars to be used to conduct research that was put off-limits by President George W. Bush.
Complex wounds affect more patients in the United States than heart attack and stroke combined, and five to seven million Americans with complex wounds account for over $20 billion in healthcare expenditures. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease.
Insmed Incorporated, a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.
Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.
› Verified 8 days ago
Jennifer Mosley, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5440 | |
Katrina Hearn, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 | |
Noelle Holmes, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5440 | |
Angela Catherine Carlini, COTA/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 | |
Elizabeth Downing, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 | |
Jodie Marie Braswell, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-744-3600 | |
Kamlesh B Arya, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 628 King James Ct, Bear, DE 19701 Phone: 302-250-4418 |